Focused On-demand Library for Zinc finger MYND domain-containing protein 10

Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.


From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Reaxense aids in their synthesis and provision.


The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.


Our high-tech, dedicated method is applied to construct targeted libraries.


 

Fig. 1. The screening workflow of Receptor.AI

Utilising molecular simulations, our approach thoroughly examines a wide array of proteins, tracking their conformational changes individually and within complexes. Ensemble virtual screening enables us to address conformational flexibility, revealing essential binding sites at functional regions and allosteric locations. Our rigorous analysis guarantees that no potential mechanism of action is overlooked, aiming to uncover new therapeutic targets and lead compounds across diverse biological functions.


Key features that set our library apart include:


  • The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.

  • The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.

  • With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.

  • Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.

PARTNER
Receptor.AI
 
UPACC
O75800

UPID:
ZMY10_HUMAN

ALTERNATIVE NAMES:
Protein BLu

ALTERNATIVE UPACC:
O75800; A6NK41; B3KU54; O14570; O75801; Q53FE6; Q8N4R6; Q8NDN6

BACKGROUND:
The Zinc finger MYND domain-containing protein 10, alternatively known as Protein BLu, is integral to axonemal structure organization and cilia motility. By facilitating the pre-assembly of dynein arms, it ensures the proper function of cilia, which is critical for various physiological processes. Its role in indirectly regulating the transcription of dynein proteins underscores its importance in cellular dynamics.

THERAPEUTIC SIGNIFICANCE:
The direct link between Zinc finger MYND domain-containing protein 10 and Primary Ciliary Dyskinesia, specifically type 22, highlights its therapeutic significance. This genetic disorder, marked by defective cilia, leads to chronic respiratory issues and can result in situs inversus. Exploring the functions of this protein offers a promising avenue for developing treatments for diseases caused by ciliary malfunctions.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.


Page 7408 of 8789